Stay updated on Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.

Latest updates to the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedThe page now shows Revision: v3.5.3 instead of Revision: v3.5.2. This reflects a minor update to the page's content or presentation.SummaryDifference0.0%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedThe site version was updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check55 days agoChange DetectedAdded Revision: v3.5.0. Deleted Revision: v3.4.3.SummaryDifference0.0%

- Check62 days agoChange DetectedRevision updated to v3.4.3 (from v3.4.2).SummaryDifference0.0%

- Check90 days agoChange DetectedThe page adds a reference to Primary peritoneal carcinoma and a Genetic and Rare Diseases Information Center resource, and removes the government funding notice. A revision note (v3.4.2) is also shown.SummaryDifference0.2%

- Check98 days agoChange DetectedA site-wide notice about funding-related delays was added, and the page revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

Stay in the know with updates to Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Paclitaxel in Ovarian Cancer Clinical Trial page.